AN2 Therapeutics (ANTX) Change in Account Payables (2021 - 2026)
AN2 Therapeutics (ANTX) reported Change in Account Payables of -$405000.0 for Q1 2026, down 65.98% year-over-year from -$1.2 million in Q1 2025, and down 150.94% quarter-over-quarter from $795000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Change in Account Payables (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Change in Account Payables data on file, last reported at -$405000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$405000.0, down 65.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$457000.0 (down 171.41% YoY), and the FY2025 annual result was -$296000.0, down 146.18% from the prior year.
- Change in Account Payables retreated to -$405000.0 in Q1 2026 per ANTX's latest filing, from $795000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.7 million in Q3 2023 and troughed at -$2.1 million in Q4 2023.
- A 5-year average of $175882.4 and a median of -$171000.0 in 2022 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 1065.5% in 2023 and fell as far as 409.4% in 2023.
- A 5-year view of Change in Account Payables shows it stood at $681000.0 in 2022, then tumbled by 409.4% to -$2.1 million in 2023, then surged by 176.22% to $1.6 million in 2024, then plunged by 50.5% to $795000.0 in 2025, then plunged by 150.94% to -$405000.0 in 2026.
- Business Quant data shows ANTX's Change in Account Payables at -$405000.0 in Q1 2026, $795000.0 in Q4 2025, and $113000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -9.42 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -405,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -405,000.00 |
| Mar 31, 2026 | -405,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Jun 30, 2025 | -960,000.00 |
| Jun 30, 2025 | -960,000.00 |
| Mar 31, 2025 | -244,000.00 |
| Mar 31, 2025 | -244,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | -174,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Jun 30, 2024 | -548,000.00 |
| Jun 30, 2024 | -548,000.00 |
| Mar 31, 2024 | -243,000.00 |
| Mar 31, 2024 | -243,000.00 |
| Dec 31, 2023 | -2.11 Mn |
| Dec 31, 2023 | -2.11 Mn |